Dyslipidemia - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 200 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dyslipidemia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Dyslipidemia - Pipeline Review, H1 2015', provides an overview of the Dyslipidemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dyslipidemia Overview 9
Therapeutics Development 10
Pipeline Products for Dyslipidemia - Overview 10
Pipeline Products for Dyslipidemia - Comparative Analysis 11
Dyslipidemia - Therapeutics under Development by Companies 12
Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 16
Dyslipidemia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Dyslipidemia - Products under Development by Companies 20
Dyslipidemia - Products under Investigation by Universities/Institutes 24
Dyslipidemia - Companies Involved in Therapeutics Development 25
Amgen Inc. 25
Arisaph Pharmaceuticals, Inc. 26
AstraZeneca PLC 27
Biocon Limited 28
Cadila Pharmaceuticals Ltd. 29
Cerenis Therapeutics Holding SA 30
Chong Kun Dang Pharmaceutical Corp. 31
CymaBay Therapeutics, Inc. 32
Daiichi Sankyo Company, Limited 33
Debiopharm International S.A. 34
Dezima Pharma BV 35
Dr. Reddy's Laboratories Limited 36
Genfit SA 37
GlaxoSmithKline plc 38
Hanmi Pharmaceuticals, Co. Ltd. 39
High Point Pharmaceuticals, LLC 40
Intas Pharmaceuticals Ltd. 41
Jenrin Discovery, Inc. 42
JW Pharmaceutical Corporation 43
Kissei Pharmaceutical Co., Ltd. 44
Kotobuki Pharmaceutical Co., Ltd. 45
Kowa Company, Ltd. 46
Kymab Limited 47
Lipicard Technologies Limited 48
Merck & Co., Inc. 49
Nippon Chemiphar Co., Ltd. 50
Novartis AG 51
Pfizer Inc. 52
Pharmena SA 53
Piramal Enterprises Limited 54
Reviva Pharmaceuticals Inc. 55
Sanofi 56
Takeda Pharmaceutical Company Limited 57
Torrent Pharmaceuticals Limited 58
Zydus Cadila Healthcare Limited 59
Dyslipidemia - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Target 62
Assessment by Mechanism of Action 64
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
(ezetimibe + rosuvastatin calcium) - Drug Profile 70
(niacin + aspirin) - Drug Profile 71
(pitavastatin + valsartan) - Drug Profile 72
(rosuvastatin calcium + ezetimibe) - Drug Profile 73
(statin + niacin + aspirin) - Drug Profile 74
4655-K09 - Drug Profile 75
anacetrapib - Drug Profile 76
ARI-3037MO - Drug Profile 78
AZ-12260493 - Drug Profile 80
BioE-1115 - Drug Profile 81
bococizumab - Drug Profile 82
BSN-852 - Drug Profile 83
C-24 - Drug Profile 84
C-3 - Drug Profile 85
Centatin - Drug Profile 86
CKD-519 - Drug Profile 87
Debio-0930B - Drug Profile 88
DEZ-001 - Drug Profile 89
DF-461 - Drug Profile 90
DGAT-1 - Drug Profile 91
DRL-17822 - Drug Profile 92
evolocumab - Drug Profile 93
GFT-505 - Drug Profile 96
GSK-2041706 - Drug Profile 99
HCP-1105 - Drug Profile 100
HCP-1305 - Drug Profile 101
HDL Receptor Enhancer - Drug Profile 102
HPP-593 - Drug Profile 103
INSUPR-001 - Drug Profile 104
JD-5037 - Drug Profile 105
K-312 - Drug Profile 106
K-877 - Drug Profile 107
KT6-971 - Drug Profile 108
KTA-439 - Drug Profile 109
KY-1020 - Drug Profile 110
LP-071 - Drug Profile 111
LT-5421 - Drug Profile 112
LT-5423 - Drug Profile 113
MAT-9001 - Drug Profile 114
MBX-8025 - Drug Profile 115
MGL-3196 - Drug Profile 117
NC-2400 - Drug Profile 119
ND-630 - Drug Profile 120
ND-654 - Drug Profile 121
P-7435 - Drug Profile 122
Peroxibrate - Drug Profile 123
pitavastatin CR - Drug Profile 124
Recombinant ApoE4 for Dyslipidemia - Drug Profile 125
RP-17000 - Drug Profile 126
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 127
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia and Type 2 Diabetes - Drug Profile 128
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 129
Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia - Drug Profile 130
Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 131
Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile 132
Small Molecules to Inhibit DGAT-1 for Metabolic Disorders - Drug Profile 133
Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 134
SPX-100 - Drug Profile 135
SPX-8522876 - Drug Profile 136
Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 137
TAP-311 - Drug Profile 138
TRC-210258 - Drug Profile 139
TRIA-662 - Drug Profile 140
VK-0214 - Drug Profile 142
ZLN-005 - Drug Profile 143
ZLN-024 - Drug Profile 144
ZYH-7 - Drug Profile 145
ZYT-1 - Drug Profile 146
Dyslipidemia - Recent Pipeline Updates 147
Dyslipidemia - Dormant Projects 168
Dyslipidemia - Discontinued Products 175
Dyslipidemia - Product Development Milestones 180
Featured News & Press Releases 180
Appendix 194
Methodology 194
Coverage 194
Secondary Research 194
Primary Research 194
Expert Panel Validation 194
Contact Us 195
Disclaimer 195

List of Tables
Number of Products under Development for Dyslipidemia, H1 2015 15
Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Development by Companies, H1 2015 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2015 29
Dyslipidemia - Pipeline by Amgen Inc., H1 2015 30
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 31
Dyslipidemia - Pipeline by AstraZeneca PLC, H1 2015 32
Dyslipidemia - Pipeline by Biocon Limited, H1 2015 33
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2015 34
Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2015 35
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 36
Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2015 37
Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 38
Dyslipidemia - Pipeline by Debiopharm International S.A., H1 2015 39
Dyslipidemia - Pipeline by Dezima Pharma BV , H1 2015 40
Dyslipidemia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2015 41
Dyslipidemia - Pipeline by Genfit SA, H1 2015 42
Dyslipidemia - Pipeline by GlaxoSmithKline plc, H1 2015 43
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 44
Dyslipidemia - Pipeline by High Point Pharmaceuticals, LLC, H1 2015 45
Dyslipidemia - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 46
Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H1 2015 47
Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H1 2015 48
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 49
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2015 50
Dyslipidemia - Pipeline by Kowa Company, Ltd., H1 2015 51
Dyslipidemia - Pipeline by Kymab Limited, H1 2015 52
Dyslipidemia - Pipeline by Lipicard Technologies Limited, H1 2015 53
Dyslipidemia - Pipeline by Merck & Co., Inc., H1 2015 54
Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 55
Dyslipidemia - Pipeline by Novartis AG, H1 2015 56
Dyslipidemia - Pipeline by Pfizer Inc., H1 2015 57
Dyslipidemia - Pipeline by Pharmena SA, H1 2015 58
Dyslipidemia - Pipeline by Piramal Enterprises Limited, H1 2015 59
Dyslipidemia - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 60
Dyslipidemia - Pipeline by Sanofi, H1 2015 61
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 62
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 63
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 64
Assessment by Monotherapy Products, H1 2015 65
Assessment by Combination Products, H1 2015 66
Number of Products by Stage and Target, H1 2015 68
Number of Products by Stage and Mechanism of Action, H1 2015 70
Number of Products by Stage and Route of Administration, H1 2015 72
Number of Products by Stage and Molecule Type, H1 2015 74
Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2015 152
Dyslipidemia - Dormant Projects, H1 2015 173
Dyslipidemia - Dormant Projects (Contd..1), H1 2015 174
Dyslipidemia - Dormant Projects (Contd..2), H1 2015 175
Dyslipidemia - Dormant Projects (Contd..3), H1 2015 176
Dyslipidemia - Dormant Projects (Contd..4), H1 2015 177
Dyslipidemia - Dormant Projects (Contd..5), H1 2015 178
Dyslipidemia - Dormant Projects (Contd..6), H1 2015 179
Dyslipidemia - Discontinued Products, H1 2015 180
Dyslipidemia - Discontinued Products (Contd..1), H1 2015 181
Dyslipidemia - Discontinued Products (Contd..2), H1 2015 182
Dyslipidemia - Discontinued Products (Contd..3), H1 2015 183
Dyslipidemia - Discontinued Products (Contd..4), H1 2015 184